rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy

Phospholipase A2 inhibitors (PLIs) are important targets in the search and development of new drugs. This study aimed at evaluating the potential of an alpha-type phospholipase A2 inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake in its recombinant form (rBaltMIP) to complement the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Toxicon (Oxford) 2016-12, Vol.124, p.53-62
Hauptverfasser:	Santos-Filho, Norival A., Sousa, Tiago S., Boldrini-França, Johara, Santos-Silva, Ludier K., Menaldo, Danilo L., Henrique-Silva, Flávio, Cintra, Adélia C.O., Laure, Helen J., Mamede, Carla C.N., Oliveira, Fábio, Riul, Thalita B., Dias-Baruffi, Marcelo, Rosa, José C., Sampaio, Suely V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antivenins - chemistry Antivenins - therapeutic use Bothrops Bothrops alternatus Complement Edema Inhibitors Mice Mice, Inbred BALB C Phospholipase Phospholipase A2 inhibitor Phospholipase A2 Inhibitors - isolation & purification Phospholipase A2 Inhibitors - therapeutic use rBaltMIP Recombinant Recombinant Proteins - isolation & purification Recombinant Proteins - therapeutic use Reptilian Proteins Snake Bites - drug therapy Snake Bites - pathology Snakes Therapy Toxicity Tests Toxins αPLI
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!